TLR1 and B-cell chronic lymphocytic leukemia: The iVAC-XS15-CLL01 trial is a FIH trial evaluating the safety and immunogenicity of a personalized peptide-based vaccination adjuvanted with the TLR1/2 ligand XS15 in CLL patients under BTKi-based treatment.